Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.

doi:10.1371/journal.pone.0231892

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.

PloS one - 1 Jan 2020

Latuszek Adrianna, Liu Yashu, Olsen Olav, Foster Randi, Cao Marc, Lovric Irena, Yuan Ming, Liu Nina, Chen Henry, Zhang Qian, Xiao Hui, Springer Carola, Ehrlich George, Kamat Vishal, Rafique Ashique, Hu Ying, Krueger Pamela, Huang Tammy, Poueymirou William, Babb Robert, Rosconi Michael P, Retter Marc W, Chen Gang, Morton Lori, Zambrowicz Brian, Cao Jingtai, Romano Carmelo, Olson William C

Abstract excerpt

Complement is a key component of the innate immune system. Inappropriate complement activation underlies the pathophysiology of a variety of diseases. Complement component 5 (C5) is a validated therapeutic target for complement-mediated diseases, but the development of new therapeutics has been limited by a paucity of preclinical models to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) properties of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen-Antibody Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement Activation

Share to Complement C5

Share to Half-Life

Share to Hemolysis

Share to Inhibitory Concentration 50

Share to Macaca fascicularis

Share to Protein Structure, Quaternary

Source

Open in PubMed Open full text

Identifiers

PMID: 32384086
DOI: 10.1371/journal.pone.0231892
PMCID: PMC7209288

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.PMID 32384086Read ↗

With complements: C3 inhibition in the clinicSemantic proximity Read ↗

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement systemSemantic proximity Read ↗

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complementSemantic proximity Read ↗

Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease.Semantic proximity Read ↗

Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodiesSemantic proximity Read ↗

First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitorSemantic proximity Read ↗

Developments in anti-complement therapy; from disease to clinical trialSemantic proximity Read ↗

Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacySemantic proximity Read ↗

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapySemantic proximity Read ↗

Complement C5 inhibition in patients with COVID-19 - a promising target?Semantic proximity Read ↗

Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting PropertiesSemantic proximity Read ↗

The impact of eculizumab on routine complement assaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.